M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

ProvoxLife Adoption Trends for Heat-Moisture Exchanger

Active, not recruiting

Conditions: Malignant Head and Neck Neoplasm

Interventions: Other: Clinical Evaluation
Procedure: Physical Examination
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2021-09-05

Last Posted Date: 2025-04-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 130

Registration Number: NCT05036330

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

Phase 2

Withdrawn

Conditions: Recurrent Prostate Carcinoma
Stage IV Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8
Metastatic Prostate Carcinoma
Stage IVA Prostate Cancer AJCC v8

Interventions: Procedure: Computed Tomography
Drug: Gallium Ga 68-labeled PSMA-11
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2021-09-05

Last Posted Date: 2024-03-07

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05034562

Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors

Early Phase 1

Active, not recruiting

Conditions: Myeloid Leukemia
Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Other: Electronic Health Record Review
Other: Photography

First Posted Date: 2021-09-05

Last Posted Date: 2025-04-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT05035706

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Patient Considerations of Social Media Account Management After Death

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Hematopoietic and Lymphoid System Neoplasm

Interventions: Other: Questionnaire Administration

First Posted Date: 2021-09-05

Last Posted Date: 2024-10-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 117

Registration Number: NCT05035667

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 1

Terminated

Conditions: Recurrent B Acute Lymphoblastic Leukemia
Refractory Lymphoblastic Lymphoma
Refractory B Acute Lymphoblastic Leukemia
Recurrent Adult Lymphoblastic Lymphoma
Refractory T Acute Lymphoblastic Leukemia
Recurrent T Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Biological: Filgrastim-sndz
Drug: Leucovorin
Drug: Mercaptopurine
Drug: Mesna
Drug: Methotrexate
Biological: Pegfilgrastim
Drug: Prednisone
Biological: Rituximab
Biological: Tagraxofusp-erzs
Drug: Vincristine

First Posted Date: 2021-09-02

Last Posted Date: 2025-04-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT05032183

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy with Hypomethylating Agents

Phase 1

Completed

Conditions: Refractory Myelodysplastic Syndrome
Refractory Chronic Myelomonocytic Leukemia

Interventions: Drug: Fostamatinib

First Posted Date: 2021-09-01

Last Posted Date: 2025-02-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT05030675

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Feasibility of Digital Thermal Monitoring to Assess Endothelium-Dependent Vasodilation in Patients Undergoing Hematopoietic Cell Transplantation (HCT)

Not Applicable

Active, not recruiting

Conditions: Vascular
Endothelial
Endothelix
Endothelial Dysfunction

Interventions: Device: Vendys II Device

First Posted Date: 2021-09-01

Last Posted Date: 2025-06-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT05029752

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Phase 2

Recruiting

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC V8
Metastatic Melanoma
Pathologic Stage IV Cutaneous Melanoma AJCC V8

Interventions: Drug: Binimetinib
Drug: Encorafenib
Other: Questionnaire Administration

First Posted Date: 2021-08-30

Last Posted Date: 2025-01-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT05026983

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

Phase 2

Active, not recruiting

Conditions: Metastatic Angiosarcoma
Recurrent Angiosarcoma
Locally Advanced Angiosarcoma

Interventions: Other: Quality-of-Life Assessment
Biological: Sintilimab

First Posted Date: 2021-08-30

Last Posted Date: 2025-05-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT05026736

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

Phase 2

Recruiting

Conditions: the Nasal Cavity
Paranasal Sinuses
Squamous Cell Carcinoma

Interventions: Drug: Pembrolizumab
Drug: Docetaxel
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2021-08-30

Last Posted Date: 2024-12-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT05027633

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy